Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM

References

• Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067.
   PubMed Web of Science ®Google Scholar
• Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018;44(6):1195–1203. doi:10.1093/schbul/sby058
   PubMed Web of Science ®Google Scholar
• Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014;10:425–448. doi:10.1146/annurev-clinpsy-032813-153657
   PubMed Web of Science ®Google Scholar
• Bellack AS, Green MF, Cook JA, et al. Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on an NIMH-sponsored workshop. Schizophr Bull. 2007;33(3):805–822. doi:10.1093/schbul/sbl035
   PubMed Web of Science ®Google Scholar
• Correll CU, Stanford AD, Claxton A, Du Y, Weiden PJ. Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study. Psychiatry Res. 2019;274:176–181. doi:10.1016/j.psychres.2019.02.021
   PubMed Web of Science ®Google Scholar
• Peters-Strickland T, Baker RA, Such P, Zhang P, Madera JJ. The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies. Neuropsychiatr Dis Treat. 2019;15:1659–1669. doi:10.2147/NDT.S198241
   PubMed Web of Science ®Google Scholar
• Harvey P, Bellack AS. Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept? Schizophr Bull. 2009;35(2):300–306. doi:10.1093/schbul/sbn171
   PubMed Web of Science ®Google Scholar
• Lambert M, Naber D, Schacht A, et al. Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatr Scand. 2008;118(3):220–229. doi:10.1111/j.1600-0447.2008.01213.x
   PubMed Web of Science ®Google Scholar
• The American Psychiatric Association (APA). Practice Guideline for the Treatment of Patients with Schizophrenia. The American Psychiatric Association (APA); 2019.
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Psychosis and Schizophrenia in Adults: Prevention and Management. National Institute for Health and Care Excellence (NICE); 2014.
   Google Scholar
• Correll CU, Martin A, Patel C, et al. Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. Schizophrenia. 2022;8(1):5. doi:10.1038/s41537-021-00192-x
   Web of Science ®Google Scholar
• Solmi M, Correll CU. The antipsychotic paradox: lessons regarding determinants of premature mortality. Eur Neuropsychopharmacol. 2022;62:1–3. doi:10.1016/j.euroneuro.2022.05.014
   PubMed Web of Science ®Google Scholar
• Correll CU, Solmi M, Croatto G, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21(2):248–271. doi:10.1002/wps.20994
   PubMed Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951. doi:10.1016/S0140-6736(19)31135-3
   PubMed Web of Science ®Google Scholar
• Schneider-Thoma J, Chalkou K, Dörries C, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet. 2022;399(10327):824–836. doi:10.1016/S0140-6736(21)01997-8
   PubMed Web of Science ®Google Scholar
• Ostuzzi G, Bertolini F, Tedeschi F, et al. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. World Psychiatry. 2022;21(2):295–307. doi:10.1002/wps.20972
   PubMed Web of Science ®Google Scholar
• Leucht S, Leucht C, Huhn M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174(10):927–942. doi:10.1176/appi.ajp.2017.16121358
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8:387–404. doi:10.1016/S2215-0366(21)00039-0
   PubMed Web of Science ®Google Scholar
• Rubio JM, Taipale H, Tanskanen A, Correll CU, Kane JM, Tiihonen J. Long-term continuity of antipsychotic treatment for schizophrenia: a nationwide study. Schizophr Bull. 2021;47(6):1611–1620. doi:10.1093/schbul/sbab063
   PubMed Web of Science ®Google Scholar
• Hargarter L, Bergmans P, Cherubin P, et al. Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia. Expert Opin Pharmacother. 2016;17(8):1043–1053. doi:10.1080/14656566.2016.1174692
   PubMed Web of Science ®Google Scholar
• Brown B, Turkoz I, Mancevski B, Mathews M. Evaluation of paliperidone palmitate long-acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia. Early Interv Psychiatry. 2020;14(4):428–438. doi:10.1111/eip.12868
   PubMed Web of Science ®Google Scholar
• Kim S, Kim S, Koh M, et al. Effects of long-acting injectable paliperidone palmitate on clinical and functional outcomes in patients with schizophrenia based on illness duration. J Clin Psychiatry. 2021;82(1):20m13446. doi:10.4088/JCP.20m13446
   PubMed Web of Science ®Google Scholar
• Risperdal Consta® (risperidone) US [package insert]. Beerse, BE: Janssen pharmaceuticals Inc; 2003. Available from: https://wwwaccessdata.fda.gov/drugsatfda_docs/label/2010/021346_s31_s35_s38_s39lbl.pdf. Accessed January 17, 2023.
   Google Scholar
• Abilify Maintena® (aripiprazole) US [package insert]. Chiyoda, JP: Otsuka Pharmaceutical Co; 2002. Available from: https://wwwaccessdata.fda.gov/drugsatfda_docs/label/2016/202971s008lbl.pdf. Accessed January 17, 2023.
   Google Scholar
• Aristada® (aripiprazole lauroxil) [US package insert]. Dublin, IR: Alkermes; 2015. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207533s000lbl.pdf. Accessed January 17, 2023.
   Google Scholar
• Invega Sustena® (paliperidone) US [package insert]. Beerse, BE: Janssen pharmaceuticals Inc; 2006. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022264s023lbl.pdf. Accessed January 17, 2023.
   Google Scholar
• Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1–24. doi:10.4088/JCP.15032su1
   PubMed Web of Science ®Google Scholar
• Anta L, Llaudó J, Ayani I, Martínez J, Litman RE, Gutierro I. A Phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia. Int Clin Psychopharmacol. 2018;33(2):79–87. doi:10.1097/YIC.0000000000000203
   PubMed Web of Science ®Google Scholar
• Llaudó J, Anta L, Ayani I, et al. Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). Int Clin Psychopharmacol. 2016;31(6):323–331. doi:10.1097/YIC.0000000000000139
   PubMed Web of Science ®Google Scholar
• Walling DP, Hassman HA, Anta L, et al. The steady-state comparative bioavailability of intramuscular Risperidone ISM and oral risperidone: an open-label, one-sequence study. Drug Des Devel Ther. 2021;15:4371–4382. doi:10.2147/DDDT.S332026
   PubMed Web of Science ®Google Scholar
• Correll CU, Litman RE, Filts Y, et al. Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation. NPJ Schizophr. 2020;6(1):37. doi:10.1038/s41537-020-00127-y
   PubMed Web of Science ®Google Scholar
• Filts Y, Litman RE, Martínez J, Anta L, Naber D, Correll CU. Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: results from a 12-month open-label extension study. Schizophr Res. 2022;239:83–91. doi:10.1016/j.schres.2021.11.030
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Association; 2016.
   Google Scholar
• Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323–329. doi:10.1034/j.1600-0447.2000.101004323.x
   PubMed Web of Science ®Google Scholar
• Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50(1–2):79–88. doi:10.1016/S0920-9964(00)00166-3
   PubMed Web of Science ®Google Scholar
• Vothknecht S, Meijer C, Zwinderman A, et al; for Genetic Risk and Outcome of Psychosis (GROUP). Psychometric evaluation of the Subjective Well-being Under Neuroleptic Treatment Scale (SWN) in patients with schizophrenia, their relatives and controls. Psychiatry Res. 2013;206(1):62–67. doi:10.1016/j.psychres.2012.09.004
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. doi:10.1093/schbul/13.2.261
   PubMed Web of Science ®Google Scholar
• Akaike H. Information theory and an extension of the maximum likelihood principle. In: Petrov B, Csáki F, editors. Second International Symposium on Information Theory. Budapest: Akadémiai Kiadó; 1998:199–213.
   Google Scholar
• Brissos S, Palhava F, Marques JG, et al. The Portuguese version of the Personal and Social Performance Scale (PSP): reliability, validity, and relationship with cognitive measures in hospitalized and community schizophrenia patients. Soc Psychiatry Psychiatr Epidemiol. 2012;47(7):1077–1086. doi:10.1007/s00127-011-0412-6
   PubMed Web of Science ®Google Scholar
• Garcia-Portilla MP, Saiz PA, Bousoño M, Bascaran MT, Guzmán-Quilo C, Bobes J. Validation of the Spanish Personal and Social Performance scale (PSP) in outpatients with stable and unstable schizophrenia. Rev Psiquiatr Salud Ment. 2011;4(1):9–18. doi:10.1016/j.rpsm.2010.11.003
   PubMed Web of Science ®Google Scholar
• Kawata AK, Revicki DA. Psychometric properties of the Personal and Social Performance scale (PSP) among individuals with schizophrenia living in the community. Qual Life Res. 2008;17(10):1247–1256. doi:10.1007/s11136-008-9400-z
   PubMed Web of Science ®Google Scholar
• Chiu EC, Hung TM, Huang CM, Lee SC, Hsieh CL. Responsiveness of the Personal and Social Performance scale in patients with schizophrenia. Psychiatry Res. 2018;260:338–342. doi:10.1016/j.psychres.2017.11.053
   PubMed Web of Science ®Google Scholar
• Nicholl D, Nasrallah H, Nuamah I, Akhras K, Gagnon D, Gopal S. Personal and social functioning in schizophrenia: defining a clinically meaningful measure of maintenance in relapse prevention. Curr Med Res Opin. 2010;26(6):1471–1484. doi:10.1185/03007991003798927
   PubMed Web of Science ®Google Scholar
• Gopal S, Hough DW, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol. 2010;25(5):247–256. doi:10.1097/YIC.0b013e32833948fa
   PubMed Web of Science ®Google Scholar
• Pandina G, Lindenmayer JP, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010;30(3):235–244. doi:10.1097/JCP.0b013e3181dd3103
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Baker RA, Eramo A, et al. Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies. Schizophr Res. 2014;159(2–3):415–420. doi:10.1016/j.schres.2014.09.019
   PubMed Web of Science ®Google Scholar
• Bigelow DA, Cutler DL, Moore LJ, McComb P, Leung P. Characteristics of state hospital patients who are hard to place. Hosp Community Psychiatry. 1988;39:181–185. doi:10.1176/ps.39.2.181
   PubMedGoogle Scholar
• Greenfield TK, McNiel DE, Binder RL. Violent behavior and length of psychiatric hospitalization. Hosp Community Psychiatry. 1989;40:809–814. doi:10.1176/ps.40.8.809
   PubMedGoogle Scholar
• Kozma CM, Dirani RG, Canuso CM, Mao L. Predicting hospital admission and discharge with symptom or function scores in patients with schizophrenia: pooled analysis of a clinical trial extension. Ann Gen Psychiatry. 2010;9:24. doi:10.1186/1744-859X-9-24
   PubMed Web of Science ®Google Scholar
• Montemagni C, Frieri T, Rocca P. Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life. Neuropsychiatr Dis Treat. 2016;12:917–929. doi:10.2147/NDT.S88632
   PubMed Web of Science ®Google Scholar
• Bozzatello P, Bellino S, Mancini I, Sandei L, Zanalda E, Rocca P. Effects on satisfaction and service engagement of paliperidone palmitate compared with oral paliperidone in patients with schizophrenia: an open label randomized controlled trial. Clin Drug Investig. 2019;39(2):169–178. doi:10.1007/s40261-018-0734-1
   PubMed Web of Science ®Google Scholar
• Lim M, Li Z, Xie H, Tan BL, Lee J. The effect of therapeutic alliance on attitudes toward psychiatric medications in schizophrenia. J Clin Psychopharmacol. 2021;41(5):551–560. doi:10.1097/JCP.0000000000001449
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67(3):453–460. doi:10.4088/JCP.v67n0317
   PubMed Web of Science ®Google Scholar
• Álamo C. Risperidone ISM as a new option in the clinical management of schizophrenia: a narrative review. Adv Ther. 2022;39(11):4875–4891. doi:10.1007/s12325-022-02299-8
   PubMed Web of Science ®Google Scholar
• Citrome L, Belcher E, Stacy S, Suett M, Mychaskiw M, Salinas GD. Management of schizophrenia with long-acting injectable antipsychotic medications: an assessment of the educational needs of clinicians. Neuropsychiatr Dis Treat. 2022;18:111–123. doi:10.2147/NDT.S326299
   PubMed Web of Science ®Google Scholar
• Potkin S, Bera R, Zubek D, Lau G. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry. 2013;13:261. doi:10.1186/1471-244X-13-261
   PubMed Web of Science ®Google Scholar
• Kubo K, Fleischhacker W, Suzuki T, Yasui-Furukori N, Mimura M, Uchida H. Placebo effects in adult and adolescent patients with schizophrenia: combined analysis of nine RCTs. Acta Psychiatr Scand. 2019;139:108–116. doi:10.1111/acps.12960
   PubMed Web of Science ®Google Scholar
• Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable versus oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol. 2013;66(8 Suppl):S37–S41. doi:10.1016/j.jclinepi.2013.01.012
   PubMed Web of Science ®Google Scholar